 |
|
Loss of Strength and Functional Decline in Duchenne's Dystrophy
Kent G. Allsop, RPT, PhD;
Fred A. Ziter, MD
Arch Neurol. 1981;38(7):406-411.
Abstract
• Clinical tests of strength and function were performed on 27 ambulatory patients with Duchenne's dystrophy every three months for 21/2 years. Linear decline of strength remains a fundamental characteristic of Duchenne's dystrophy. Although generally considered a homogeneous disease, our patients showed a broad spectrum of disability. Current tests of functional ability are poor measures of disease progression during most of the ambulatory period, since efficiency is maintained despite continuous decline in muscle strength. However, after this "latent" phase, failure of certain functions paralleled muscle deterioration closely, since task loss occurred within a narrow range of composite muscle strength. Finally, data on changes in body weight showed that most patients were excessively thin rather than obese. It is concluded that manual muscle strength testing remains the most valid method of monitoring disease progression and must be included in patient assessment.
Author Affiliations
From the Department of Physical Therapy (Dr Allsop), College of Health, and the Division of Pediatric Neurology (Dr Ziter), Departments of Pediatrics and Neurology, College of Medicine, University of Utah, Salt Lake City.
Footnotes
Accepted for publication Sept 13, 1980.
Reprint requests to Department of Neurology, University of Utah Medical Center, 50 N Medical Dr, Salt Lake City, UT 84132 (Dr Ziter).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
Bonifati et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:1177-1179.
ABSTRACT
| FULL TEXT
Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects
Lindeman et al.
Clin Rehabil 1998;12:127-135.
ABSTRACT
Evaluation of a Program for Long-Term Treatment of Duchenne Muscular Dystrophy. Experience at the University Hospitals of Cleveland
VIGNOS et al.
JBJS 1996;78:1844-52.
ABSTRACT
| FULL TEXT
Clinical Investigation of Duchenne Muscular Dystrophy: A Methodology for Therapeutic Trials Based on Natural History Controls
Mendell et al.
Arch Neurol 1987;44:808-811.
ABSTRACT
Prednisone Treatment in Duchenne Muscular Dystrophy: Long-term Benefit
DeSilva et al.
Arch Neurol 1987;44:818-822.
ABSTRACT
Drug Trial of Superoxide Dismutase in Duchenne's Muscular Dystrophy
Stern et al.
Arch Neurol 1982;39:342-346.
ABSTRACT
|
